This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women

This study has been completed.
Information provided by (Responsible Party):
Unigene Laboratories Inc. Identifier:
First received: March 16, 2011
Last updated: February 21, 2013
Last verified: January 2013
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.

Condition Intervention Phase
Postmenopausal Osteoporosis Drug: PTH analog Drug: Placebo Drug: Forsteo (Teriparatide) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo® in Postmenopausal Women With Osteoporosis

Resource links provided by NLM:

Further study details as provided by Unigene Laboratories Inc.:

Primary Outcome Measures:
  • % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 [ Time Frame: 24 weeks from baseline ]

Secondary Outcome Measures:
  • % Change From Baseline in Bone Resorption Marker (CTx-1) at Week 24 [ Time Frame: 24 weeks from baseline ]
    Serum collagen type I (CTx-1) fragments generated during osteoclastic bone turnover are biomarkers for bone resorption. β-CrossLaps electrochemiluminescent sandwich immunoassay was used.

  • Systemic Absorption of PTH at Week 24 [ Time Frame: 24 weeks ]
    AUC: (PTH analog tablets timepoints - baseline to 5.75 hours) (Forsteo injection timepoints - baseline to 2 hours)

  • % Change From Baseline in Bone Formation Marker (P1NP) at Week 24 [ Time Frame: 24 weeks from baseline ]

Enrollment: 97
Study Start Date: February 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PTH analog tablet
PTH(1-31) 5 mg tablet, once daily
Drug: PTH analog
A recombinant 1-31 amino acid fragment of PTH.
Other Name: PTH(1-31)
Placebo Comparator: Placebo
Placebo matching tablet, once daily
Drug: Placebo
Active Comparator: Forsteo
Forsteo (teriparatide) 20 mcg SC Injection, once daily
Drug: Forsteo (Teriparatide)
A recombinant 1-34 amino acid fragment of PTH.
Other Name: Forteo (US)

Detailed Description:
The choice of a 24-week treatment period was based on published studies of PTH which demonstrate its potential to produce a statistically significant increase in BMD in patients with postmenopausal osteoporosis within that observation period.

Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy postmenopausal women (45-80 years old) with a diagnosis of osteoporosis

Exclusion Criteria:

  • Use of estrogen or hormone replacement therapy
  • Use of bisphosphonates, strontium ranelate or denosumab
  • Use of parathyroid analogues or other bone metabolic agents
  • Medical conditions which might alter bone metabolism
  • Any known clinically significant disease affecting calcium metabolism or history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia
  • Impairment of thyroid function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01321723

Aalborg, Denmark
Ballerup, Denmark
Vejle, Denmark
Tallinn, Estonia
Sponsors and Collaborators
Unigene Laboratories Inc.
Principal Investigator: Christence S Teglbjaerg, MD CCBR
Principal Investigator: Bettina S Nedergaard, MD CCBR
Principal Investigator: Peter Alexandersen, MD CCBR
Principal Investigator: Ivo Valter, MD CCBR
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Unigene Laboratories Inc. Identifier: NCT01321723     History of Changes
Other Study ID Numbers: UGL-OR1001
Study First Received: March 16, 2011
Results First Received: December 12, 2012
Last Updated: February 21, 2013

Keywords provided by Unigene Laboratories Inc.:
Bone Diseases, Metabolic
Bone Diseases
Bone Density Conservation Agents

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on August 21, 2017